Mostrar el registro sencillo del ítem

Estimación del riesgo cardiovascular con la escala Framingham calibrada, en población santandereana

dc.contributor.advisorParra Serrano, Gustavo Adolfospa
dc.contributor.advisorPlata Vanegas, Silvia Constanzaspa
dc.contributor.authorNavas López, Julián Alonsospa
dc.coverage.spatialSantander (Colombia)spa
dc.date.accessioned2020-06-26T19:59:54Z
dc.date.available2020-06-26T19:59:54Z
dc.date.issued2018
dc.identifier.urihttp://hdl.handle.net/20.500.12749/1732
dc.description.abstractIntroducción: Las Enfermedades Cardiovasculares son la principal causa de muerte y discapacidad a nivel mundial y en Colombia, siendo el riesgo cardiovascular la probabilidad que tiene un individuo de presentarlas. Existen múltiples modelos que intentan predecir la probabilidad de morbimortalidad debida a enfermedad cardiovascular en un tiempo determinado, sin embargo, hasta el momento, solo las escalas de PROCAM y Framingham 2008 han sido validadas en nuestro medio. En Colombia, son escasos los estudios que categoricen el riesgo cardiovascular poblacional y Santander hasta el momento no dispone de un estudio enfocado a categorizar el riesgo cardiovascular, desconociendo el perfil global del mismo. Objetivo: Determinar el perfil de riesgo cardiovascular y la mortalidad a 10 años mediante la utilización de la escala de Framingham calibrada para Colombia en población santandereana. Resultados: La población estudio se conformó por 577 personas de 30 a 64 años. La distribución por sexo fue predominantemente femenina (61,7%). Más de 2 tercios tenían como máximo nivel educativo primaria o secundaria, el 58,4% residía en área urbana. La prevalencia de los principales factores de riesgo fue 75,3% para sobrepeso/obesidad, 49,9% Hipercolesterolemia, 26,3% hipertensión arterial, 11% diabetes mellitus y 7,1% tabaquismo activo. Al aplicar la escala de Framingham calibrada para Colombia, se estimó una mediana de riesgo cardiovascular de 3,4% (2,1% mujeres y 5,9% hombres). La población evidenció un riesgo bajo en el 77,6%, intermedio 13,2% y alto en el 9,2%. No hubo una diferencia en el riesgo cardiovascular según el área de procedencia o estrato socioeconómico.Conclusiones: Se evidenció un riesgo cardiovascular global bajo, sin diferencias respecto al sexo o al área de residencia y se observó una dramática prevalencia de sobrepeso y obesidad, así como una tendencia de aumento de los demás factores de riesgo cardiovascular al ser comparados con los otros estudios departamentales o nacionales.spa
dc.description.tableofcontents1. DESCRIPCIÓN DEL PROYECTO ............................................................................................... 14 1.1 PLANTEAMIENTO Y JUSTIFICACIÓN DEL PROBLEMA .................................................... 14 1.2 PREGUNTA DE INVESTIGACIÓN .................................................................................... 15 2. MARCO TEÓRICO Y ESTADO DEL ARTE ................................................................................. 17 3. OBJETIVOS ............................................................................................................................. 27 3.1 OBJETIVO PRINCIPAL ..................................................................................................... 27 3.2 OBJETIVOS SECUNDARIOS: ........................................................................................... 27 4. METODOLOGÍA PROPUESTA ................................................................................................ 29 4.1 TIPO DE ESTUDIO .......................................................................................................... 29 4.2 POBLACIÓN ................................................................................................................... 29 4.3 CRITERIOS DE SELECCIÓN ............................................................................................. 29 4.4 CALCULO DEL TAMAÑO DE MUESTRA .......................................................................... 29 4.5 MUESTREO .................................................................................................................... 31 4.6 RECOLECCIÓN DE LA INFORMACIÓN ............................................................................ 32 4.7 VARIABLES ..................................................................................................................... 33 4.8 ANÁLISIS DE DATOS ...................................................................................................... 36 4.9 CONSIDERACIONES ÉTICAS ........................................................................................... 36 5. RESULTADOS ................................................................................................................ 39 6. DISCUSIÓN ................................................................................................................... 47 7. CONCLUSIONES ............................................................................................................ 52 8. BIBLIOGRAFÍA ............................................................................................................... 54spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleEstimación del riesgo cardiovascular con la escala Framingham calibrada, en población santandereanaspa
dc.title.translatedEstimation of cardiovascular risk with the calibrated Framingham scale, in the population of Santandereng
dc.degree.nameEspecialista en Medicina Internaspa
dc.coverageFloridablanca (Santander, Colombia)spa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Medicina Internaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsHigh blood pressureeng
dc.subject.keywordsCardiovascular riskeng
dc.subject.keywordsDiabetes mellituseng
dc.subject.keywordsCardiovascular diseaseseng
dc.subject.keywordsFramingham scaleeng
dc.subject.keywordsMedicineeng
dc.subject.keywordsInternal medicineeng
dc.subject.keywordsInvestigationseng
dc.subject.keywordsComplicationseng
dc.subject.keywordsPatientseng
dc.subject.keywordsPrevention and controleng
dc.subject.keywordsGlobal cardiovascular riskeng
dc.subject.keywordsCardiometabolic healtheng
dc.subject.keywordsPublic healtheng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.relation.referencesNavas López, Julián Alonso (2018). Estimación del riesgo cardiovascular con la escala Framingham calibrada, en población santandereana. Floridablanca (Santander, Colombia) : Universidad Autónoma de Bucaramanga UNABspa
dc.relation.references1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.spa
dc.relation.references2. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017.spa
dc.relation.references3. Laslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the american college of cardiology. J Am Coll Cardiol [Internet]. Elsevier Inc.; 2012;60(25 SUPPL.):S1–49. Available from: http://dx.doi.org/10.1016/j.jacc.2012.11.002spa
dc.relation.references4. Alegría Ezquerra E, Alegría Barrero A, Alegría Barrero E. Estratificación del riesgo cardiovascular: Importancia y aplicaciones. Rev Española Cardiol Supl. 2012;12(SUPPL.3):8–11.spa
dc.relation.references5. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 SUPPL. 1):49–76.spa
dc.relation.references6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 PART B):2889–934.spa
dc.relation.references7. Muñoz OM, García ÁA, Fernández-Ávila D, Higuera A, Ruiz ÁJ, Aschner P, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. Rev Colomb Cardiol [Internet]. 2015;22(6):263–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0120563315001059spa
dc.relation.references8. Muñoz M. Oscar, Rodríguez I. Nohora, Ruiz Alvaro RM. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol. 2014;21(4):202–12.spa
dc.relation.references9. Libby, P.; Ridker, P. M.; Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature [Internet]. 2011;473:317–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21593864spa
dc.relation.references10. Ministerio de Salud de Colombia. Así vamos en salud. Mortalidad por Enfermedades Crónicas. [Internet]. 2016. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asi s-colombia-2016.pdfspa
dc.relation.references11. Organización Panamericana de la Salud. Perfil de Enfermedades Cardiovasculares en México [Internet]. 2011. p. 1. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&Ite mid=270&gid=27482&lang=es.spa
dc.relation.references12. Observatorio de Salud Pública de Santander. Secretaría de Salud de Santander. Diagnóstico de Salud de Santander. 2012 [Internet]. Revista del Observatorio de Salud Pública de Santander. 2012. Available from: https://www.minsalud.gov.co/plandecenal/mapa/Analisis-de-Situacion-Salud- Santander-2011.pdfspa
dc.relation.references13. Observatorio de Salud Pública de Santander. Secretaría de Salud de Santander. Indicadores Básicos. Situación de Salud en Santander. [Internet]. 2013. p. 60. Available from: https://web.observatorio.co/publicaciones/indicadores_basicos_de_salud_2015.p dfspa
dc.relation.references15. Patel SA, Winkel M, Ali MK, Narayan KMV, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: National and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163(4):245–53.spa
dc.relation.references16. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899–911.spa
dc.relation.references17. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92.spa
dc.relation.references18. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, et al. Association between advanced age and vascular disease in different arterial territories: A population database of over 3.6 million subjects. J Am Coll Cardiol [Internet]. Elsevier Inc.; 2013;61(16):1736–43. Available from: http://dx.doi.org/10.1016/j.jacc.2013.01.054spa
dc.relation.references19. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514–20.spa
dc.relation.references20. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008;117(6):743–53.spa
dc.relation.references21. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353(9164):1547–57.spa
dc.relation.references22. Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: Analysis of the telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (TRANSCEND) and the ongoing telmisartan alone and in combinatio. Circulation. 2012;126(8):934–41.spa
dc.relation.references23. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors and Coronary Heart Disease. Circulation. 1999;99:1165–72.spa
dc.relation.references24. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal Estrogen Therapy and Cardiovascular Disease. Ten-Year Follow-up from the Nurses’ Health Study. New Engl Jourlan Med [Internet]. New England Journal of Medicine (NEJM/MMS); 1991 Sep 12 [cited 2017 Jul 24];(11):756–62. Available from: http://www.nejm.org/doi/full/10.1056/NEJM199109123251102#t=articlespa
dc.relation.references25. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA [Internet]. 1991 Apr 10 [cited 2017 Jul 24];265(14):1861–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2005736spa
dc.relation.references26. Garcia M, Mulvagh SL, Merz CNB, Buring JE, Manson JAE. Cardiovascular disease in women: Clinical perspectives. Circ Res. 2016;118(8):1273–93.spa
dc.relation.references27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004;364(9438):937–52.spa
dc.relation.references28. O’Donnell MJ, Denis X, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet. 2010;376(9735):112–23.spa
dc.relation.references29. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet [Internet]. Elsevier Ltd; 2016;388(10046):761–75. Available from: http://dx.doi.org/10.1016/S0140- 6736(16)30506-2spa
dc.relation.references30. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: The INTERHEART Latin American study. Circulation. 2007;115(9):1067–74.spa
dc.relation.references31. Ministerio de la Protección Social. Encuesta Nacional de Salud 2007 [Internet]. 2007. p. 343. Available from: https://www.minsalud.gov.co/Documentos y Publicaciones/ENCUESTA NACIONAL.pdfspa
dc.relation.references32. Bautista LE, Oróstegui M, Vera LM, Prada GE, Orozco LC, Herrán OF. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil. 2006;13(5):769–75.spa
dc.relation.references33. Secretaria de Salud de Santander, Observatorio de Salud Publica de Santander. Factores de riesgo para enfermedades crónicas en Santander: Método STEPwise [Internet]. Observatorio de Salud Publica de Santander. 2011. 172 p. Available from: http://bases.bireme.br/cgibin/ wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=LILACS&lan g=p&nextAction=lnk&exprSearch=649085&indexSearch=ID%5Cnhttp://www.who. int/chp/steps/2010_STEPS_Survey_Colombia.pdf%5Cnhttp://www.observatorio.s aludsanspa
dc.relation.references34. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–81.spa
dc.relation.references35. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24(11):987–1003.spa
dc.relation.references36. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study (vol 105, pg 310, 2002). Circulation. 2002;105(7):900.spa
dc.relation.references37. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: The INTERHEART Modifiable Risk Score. Eur Heart J. 2011;32(5):581–90.spa
dc.relation.references38. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. N Engl J Med. 2014;371(9):818–27.spa
dc.relation.references39. Álvarez-Ceballos JC, Alvarez-Múñoz AM, Carvajal-Gutiérrez W, González MM, Duque JL, Nieto-Cárdenas OA. Determinación del riesgo cardiovascular en una población. Rev Colomb Cardiol [Internet]. 2016;24(xx):1, 8. Available from: http://www.sciencedirect.com/science/article/pii/S0120563316301395spa
dc.relation.references40. Navarro E, Vargas RF. Riesgo coronario según ecuación de Framingham en adultos con síndrome metabólico de la ciudad de Soledad, Atlántico. 2010. Rev Colomb Cardiol [Internet]. Elsevier; 2012;19(3):109–18. Available from: http://linkinghub.elsevier.com/retrieve/pii/S012056331270116Xspa
dc.relation.references41. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640–5.spa
dc.contributor.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000140148*
dc.contributor.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001520895*
dc.contributor.scopushttps://www.scopus.com/authid/detail.uri?authorId=57212741601*
dc.subject.lembHipertensión arterialspa
dc.subject.lembRiesgo cardiovascularspa
dc.subject.lembDiabetes mellitusspa
dc.subject.lembEnfermedades cardiovascularesspa
dc.subject.lembEscala Framinghamspa
dc.subject.lembMedicinaspa
dc.subject.lembMedicina internaspa
dc.subject.lembInvestigacionesspa
dc.subject.lembComplicacionesspa
dc.subject.lembPacientesspa
dc.subject.lembPrevención y controlspa
dc.description.abstractenglishIntroduction: Cardiovascular Diseases are the main cause of death and disability worldwide and in Colombia, with cardiovascular risk being the probability that an individual has of presenting them. There are multiple models that attempt to predict the probability of morbidity and mortality due to disease cardiovascular disease in a given time, however, so far, only the PROCAM and Framingham 2008 scales have been validated in our setting. In Colombia, there are few studies that categorize cardiovascular risk population and Santander so far does not have a study focused on categorize cardiovascular risk, ignoring its global profile. Objective: To determine the cardiovascular risk profile and mortality at 10 years using the Framingham scale calibrated for Colombia in Santander population. Results: The study population consisted of 577 people aged 30 to 64 years. The distribution by sex was predominantly female (61.7%). More than 2 thirds had a primary or secondary educational level at most, 58.4% resided in the area urban. The prevalence of the main risk factors was 75.3% for overweight / obesity, 49.9% hypercholesterolemia, 26.3% arterial hypertension, 11% diabetes mellitus and 7.1% active smoking. When applying the Framingham scale calibrated for Colombia, a median cardiovascular risk of 3.4% was estimated (2.1% women and 5.9% men). The population showed a low risk in 77.6%, intermediate 13.2% and high in 9.2%. There was no difference in cardiovascular risk according to the area of ​​origin or socioeconomic stratum. Conclusions: A low global cardiovascular risk was evidenced, without differences with respect to sex or area of ​​residence and a dramatic prevalence of overweight and obesity, as well as an increasing trend of the other factors of cardiovascular risk when compared with the other departmental studies or national.eng
dc.subject.proposalRiesgo cardiovascular global
dc.subject.proposalSalud cardiometabólica
dc.subject.proposalSalud pública
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.contributor.researchgroupObservatorio de Salud Pública de Santanderspa
dc.contributor.researchgroupGrupo de Investigaciones Clínicasspa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa


Ficheros en el ítem

Thumbnail
Nombre:
2018_Tesis_Julian_Alonso_Navas ...
Tamaño:
864.8Kb
Formato:
PDF
Descripción:
Tesis
Ver/
Thumbnail
Nombre:
2018_Licencia_Julian_Alonso_Na ...
Tamaño:
132.5Kb
Formato:
PDF
Descripción:
Licencia
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia